Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635954 · ClinicalTrials.gov registry record
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
A clinical trial of Cancer and Immunotherapy, sponsored by Oxford Biodynamics.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 3
- Study locations
NCT06635954: Recruiting study of Cancer and Immunotherapy, sponsored by Oxford Biodynamics.
NCT06635954 is a study of Cancer and Immunotherapy that is actively recruiting participants, run by Oxford Biodynamics. The registered enrollment target is 2,000 participants, below the 3,488-participant average among 615 other Cancer trials with a reported enrollment target (43% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06635954, a study of Cancer and Immunotherapy, is actively recruiting participants, sponsored by Oxford Biodynamics.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.
Primary Outcome
At the time of enrollment, case report forms will be completed that capture the patient's current and previous treatments, stage of disease, and prognosis. After receiving results from Episwitch CiRT, a follow up case report form will be completed that captures the response prediction from the test as well as the patient's response to their current treatment, and whether or not that treatment is an ICI therapy. The patients on ICI that receive results that indicate low probability of response wi
Conditions Studied
Study Locations (3)
Connecticut
- Eastern Connecticut Hematology and Oncology - Norwich
Georgia
- Cancer Center of Middle Georgia - Dublin
South Carolina
- Carolina Blood and Cancer Care Associates - Rock Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2027-05-14 |
What NCT06635954 shows while recruiting
NCT06635954 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,488-participant average among 615 other Cancer trials with a reported enrollment target (43% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06635954 reports a single indexed study location in Connecticut, Georgia, South Carolina.
Frequently Asked Questions
What is clinical trial NCT06635954 about?
NCT06635954 is a clinical study titled "A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.". The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to act...
What is the current status of trial NCT06635954?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2024-05-14. Estimated completion is 2027-05-14.
What conditions does trial NCT06635954 study?
This clinical trial studies the following conditions: Cancer, Immunotherapy, PD-1, Immune Checkpoint Therapy, PD-L1.
Who is sponsoring clinical trial NCT06635954?
This trial is sponsored by Oxford Biodynamics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635954 being conducted?
This trial has 3 study locations across Connecticut, Georgia, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06635954's enrollment target sits among peer trials
2,000 56th of 615 higher than 553 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI